<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402909</url>
  </required_header>
  <id_info>
    <org_study_id>CDJN608AUS13</org_study_id>
    <nct_id>NCT00402909</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone</brief_title>
  <official_title>A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Compare the Safety and Efficacy of Nateglinide vs. Placebo in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Basal Insulin Glargine in Combination With Metformin and/or Thiazolidinedione (Pioglitazone or Rosiglitazone)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of adding nateglinide to treatment with basal
      insulin glargine, metformin and/or thiazolidinedione (pioglitazone or rosiglitazone), for
      patients with type 2 diabetes who are not achieving glycemic control with glargine, metformin
      and/or thiazolidinedione only.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in hemoglobin (Hb)_A1c</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 2-hour postprandial glucose during standardized meal test</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving American Diabetes Association ADA goal of HbA1c &lt;7.0%</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving reduction in HbA1c of 0.5%</measure>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nateglinide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/female, age 18-78 inclusive

          -  Type 2 diabetes, taking glargine, metformin and/or thiazolidinedione for 3 months
             prior to screening, stable doses for 2 months prior to screening

          -  HbA1c 7.0-8.5% inclusive

          -  Fasting plasma glucose &lt;240 mg/dL at screening

          -  Body Mass Index 22-41 kg/m2

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Other investigational drugs within 30 days of screening

          -  Treatment with other anti-diabetic medications other than metformin, glargine and/or
             thiazolidinedione

          -  History of type 1 diabetes

          -  Abnormal kidney function

          -  History of acute diabetic complications

          -  Congestive heart failure requiring treatment

          -  Myocardial infarction, coronary artery surgery, stroke within 6 months of screening

          -  Liver disease, liver enzymes more than 3 times upper limit of normal

          -  Fasting triglycerides &gt;700 mg/dL within past 12 weeks

          -  Acute infections or other conditions that may affect blood sugar or may interfere with
             interpretation of study data

          -  Treatment with corticosteroids

          -  Blood donation within past 12 weeks

        Other protocol-defined inclusion/exclusion criterial may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2552</url>
    <description>Results for CDJN608AUS13 from the Novartis Clinical Trials website</description>
  </link>
  <link>
    <url>http://professional.diabetes.org/abstract/effects-nateglinide-combination-basal-insulin-glargine-metformin-andor-thiazolidinedione</url>
    <description>American Diabetes Association 68th Scientific Sessions (2008)</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes,</keyword>
  <keyword>fasting glucose,</keyword>
  <keyword>postprandial glucose,</keyword>
  <keyword>blood sugar,</keyword>
  <keyword>HbA1c,</keyword>
  <keyword>insulin,</keyword>
  <keyword>glargine,</keyword>
  <keyword>metformin,</keyword>
  <keyword>thiazolidinedione</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>2,4-thiazolidinedione</mesh_term>
    <mesh_term>Nateglinide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

